Talabostat - BioXcel Therapeutics

Drug Profile

Talabostat - BioXcel Therapeutics

Alternative Names: BXCL 701

Latest Information Update: 16 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inveni
  • Developer BioXcel Therapeutics
  • Class Antineoplastics; Boronic acids; Dipeptides; Pyrrolidines; Small molecules
  • Mechanism of Action Dipeptidyl peptidase 8 inhibitors; Dipeptidyl peptidase 9 inhibitors; Fibroblast activation protein antagonists; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 16 May 2017 BioXcel Therapeutics plans a phase Ib/II trial for Solid tumours (Combination therapy) in Q2 2017 (BioXcel website, Inveni website, April 2017)
  • 11 May 2017 Chemical structure information added
  • 01 Apr 2017 Preclinical trials in Solid tumours in USA (PO) (BioXcel pipeline, April 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top